Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
CYP2C19 encodes a member of the cytochrome P450 superfamily of enzymes. Zusätzlich bieten wir Ihnen CYP2C19 Antikörper (39) und CYP2C19 Proteine (3) und viele weitere Produktgruppen zu diesem Protein an.
Showing 4 out of 20 products:
Report association of CYP2C19 genotype with bleeding in Serbian STEMI patients who have undergone primary PCI (zeige SERPINA5 ELISA Kits) and treatment with clopidogrel.
Personalized treatment with clopidogrel or ticagrelor based on CYP2C19 genotype status ultimately led to improved clinical outcomes in acute coronary syndrome patients treated with percutaneous coronary intervention.
CYP2C19*2 Polymorphism is associated with drug resistance in Breast Cancer.
Comparisons of pharmacokinetics of 25 substrates CYP2C9 (zeige CYP2C9 ELISA Kits), CYP2C19, or CYP2D6 (zeige CYP2D6 ELISA Kits) in healthy Chinese and European subjects (classified with same enzyme activity) suggest that, for most substrates, limited interethnic pharmacokinetic differences exist (according to the databases used in this study). (CYP2C9 (zeige CYP2C9 ELISA Kits) = cytochrome P450 (zeige CYP ELISA Kits) family 2 subfamily C (zeige CYP ELISA Kits) member 9; CYP2D6 (zeige CYP2D6 ELISA Kits) = cytochrome P450 (zeige CYP ELISA Kits) family 2 subfamily D (zeige CYP ELISA Kits) member 6)
We documented a different effect of CYP2C19 and P2Y12 (zeige P2RY12 ELISA Kits) receptor polymorphisms on platelet reactivity and cardiovascular outcome in coronary artery disease patients after percutaneous coronary intervention on clopidogrel treatment. Importantly, increased platelet reactivity adversely affects the cardiovascular outcome independently of the studied polymorphisms.
CYP2C19*2 and elevated BMI are associated with clopidogrel HTPR. However, CYP2C19*2 genotyping doesn't predict clopidogrel response sufficiently.
Results suggest a role of cytochrome P450 2C19 (CYP2C19) gene variants as a potential marker of Clopidogrel response.
There is an association between cyp2c19 and loss of function allele status of clopidrogrel for stroke risk reduction
The identified allele frequencies were CYP2C19*1 (64.33%), *2 (31.06%) and *3 (4.61%). The major prevalent genotype combinations were CYP2C19 *1/*1 (41.73%) and *1/*2 (39.65%). In the Hakka population, frequencies of the CYP2C19 *2 and *3 variants were observed to be close to those previously identified in Chinese and several other Asian populations.
CYP2C19 polymorphisms significantly impacted systemic exposure and metabolism pathways of BMS-823778 in humans.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.
cytochrome P450 2C
, (R)-limonene 6-monooxygenase
, (S)-limonene 6-monooxygenase
, (S)-limonene 7-monooxygenase
, S-mephenytoin 4-hydroxylase
, cytochrome P-450 II C
, cytochrome P450 2C19
, cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19
, cytochrome P450-11A
, cytochrome P450-254C
, flavoprotein-linked monooxygenase
, mephenytoin 4'-hydroxylase
, mephenytoin 4-hydroxylase
, microsomal monooxygenase
, xenobiotic monooxygenase